Efficacy of nimotuzumab (hR3) conjugated with

The humanized monoclonal antibody hR3, both alone and in combination with other chemotherapeutic agents and radiotherapy, can be used to treat head and neck cancers. Substantial progress has been made in the development of targeted radioimmunotherapy using iodine-131 (hR3 was labeled withThe purified radioimmunoconjugates with specific activities of 187-191 MBq/mg had radiochemical purity98% and80% immunoreactivity with HEp-2 cells. Mice with HEp-2 xenografts treated with